June 14, 2010

Alligator Bioscience AB appoints Sibylle Lenz as Chief Executive Officer
Read more >>
April 15, 2010
Alligator Bioscience AB,  Annual General Meeting
Read more>>
15 april 2010

Del 2 av riktad emission tillför Alligator Bioscience AB drygt 5 MSEK

Denna andra del av den riktade emissionen tillför Alligator Bioscience AB 5.025.000 SEK (av de 5,6 miljoner SEK som återstod av bemyndigandet som  gavs vid  årsstämman 2009.  Emissionskursen, 15 kr per aktie, var samma som vid första delen av emissionen som genomfördes under 2009.

Antalet aktier som tillförs är 335.000. Totala antalet aktier efter emissionen är 15.285.820.

12 april 2010

Ledningsförändring i Alligator Bioscience AB

Läs mer >>

Descriptions of activities 2009
Descriptions of activities 2009>>

We use our FIND® protein optimization technology platform to develop innovative antibody and protein based drug candidates for unmet medical needs within Inflammation and Cancer
ADC-1004 Protection Against I/R Injury
Ischemia Reperfusion (I/R) injury is a serious complication after e.g. myocardial infarction treated with balloon dilatation, for which no treatment is available today. Alligator Bioscience has created a drug candidate against this inflammatory condition.
READ MORE ...		  
        
ADC-1001 Second Generation IL-1Ra
Our FIND® technology has proven to be very useful in creating second generation biopharmaceuticals. Alligator Bioscience has made a second generation drug candidate of Anakinra (Kineret®) with increased receptor affinity compared to Anakinra.
READ MORE …
 

Immunotherapy of Cancer                   
Cancer immunotherapy aims at stimulating the immune system of the patients to eliminate cancer cells and prevent metastasis. Alligator Bioscience is developing a novel immunotherapeutic treatment that provides systemic anti-cancer effect and immunity, with minimal systemic side effects.
READ MORE...

        
   
Sibylle Lenz, CEO
"Alligator Bioscience is the perfect partner for the optimization and development of biopharmaceuticals, based on our FIND technology. Furthermore, Alligator Bioscience has a pipeline of innovative development candidates within oncology and inflammation." 

Bengt Larsson, CMO
“ADC-1004 has the potential to become a standard add-on treatment in any situation where ischemia reperfusion injury is a risk, including acute myocardinal infarction treated with PCI, stroke treated with thrombolysis and at transplantation. No treatment is yet available to reduce ischemia reperfusion injury."

Peter Ellmark, Senior Scientist

“I believe that the immunotherapy platform that we develop will be very effective in treating many different cancer forms. It has the potential to provide clear medical benefits in term of safety, efficacy, and convenience to patients with serious and life-threatening disease.”


Christina Furebring, VP R&D
“We use our FIND® technology to redesign the protein to best suit the specific therapeutic requirements. We are not limited to native proteins or by constrains in conventional protein engineering techniques.”
Alligator Bioscience AB :: Scheelevägen 19A :: 223 70 Lund :: Phone: + 46 (0)46 286 4280 :: Fax: + 46 (0)46 286 4290
Copyright © 2008 Alligator Bioscience AB. All rights reserved